CLO22-088: Phase II Trial of Trifluridine/Tipiracil in Combination With Irinotecan in Advanced Biliary Tract Cancers (BTCs)

Authors:
Sri Harsha Tella Mayo Clinic Minnesota, Rochester, MN

Search for other papers by Sri Harsha Tella in
Current site
Google Scholar
PubMed
Close
 MBBS, FACP
,
Jaclynn Wessling Mayo Clinic Minnesota, Rochester, MN

Search for other papers by Jaclynn Wessling in
Current site
Google Scholar
PubMed
Close
 MD
,
Foster Nathan Mayo Clinic Minnesota, Rochester, MN

Search for other papers by Foster Nathan in
Current site
Google Scholar
PubMed
Close
 MS
,
Shi Qian Mayo Clinic Minnesota, Rochester, MN

Search for other papers by Shi Qian in
Current site
Google Scholar
PubMed
Close
 PhD
,
Tran Nguyen Mayo Clinic Minnesota, Rochester, MN

Search for other papers by Tran Nguyen in
Current site
Google Scholar
PubMed
Close
 MD
,
Robert McWillimas Mayo Clinic Minnesota, Rochester, MN

Search for other papers by Robert McWillimas in
Current site
Google Scholar
PubMed
Close
 MD
,
Alberts Steven Mayo Clinic Minnesota, Rochester, MN

Search for other papers by Alberts Steven in
Current site
Google Scholar
PubMed
Close
 MD
,
Minetta Liu Mayo Clinic Minnesota, Rochester, MN

Search for other papers by Minetta Liu in
Current site
Google Scholar
PubMed
Close
 MD
,
Mitesh Borad Mayo Clinic Minnesota, Rochester, MN

Search for other papers by Mitesh Borad in
Current site
Google Scholar
PubMed
Close
 MD
,
Wen Wee Ma Mayo Clinic Minnesota, Rochester, MN

Search for other papers by Wen Wee Ma in
Current site
Google Scholar
PubMed
Close
 MD
,
Mindy Hartgers Mayo Clinic Minnesota, Rochester, MN

Search for other papers by Mindy Hartgers in
Current site
Google Scholar
PubMed
Close
 APRN, CNP, MS
,
Leslie Washburn Mayo Clinic Minnesota, Rochester, MN

Search for other papers by Leslie Washburn in
Current site
Google Scholar
PubMed
Close
 MPAS, PA-C
,
Fruth Briant Mayo Clinic Minnesota, Rochester, MN

Search for other papers by Fruth Briant in
Current site
Google Scholar
PubMed
Close
,
Martin Fernandezzapico Mayo Clinic Minnesota, Rochester, MN

Search for other papers by Martin Fernandezzapico in
Current site
Google Scholar
PubMed
Close
 MD
,
Tara L Hogenson Mayo Clinic Minnesota, Rochester, MN

Search for other papers by Tara L Hogenson in
Current site
Google Scholar
PubMed
Close
 MS
,
Henry Pitot Mayo Clinic Minnesota, Rochester, MN

Search for other papers by Henry Pitot in
Current site
Google Scholar
PubMed
Close
 MD
,
Zhaohui Jin Mayo Clinic Minnesota, Rochester, MN

Search for other papers by Zhaohui Jin in
Current site
Google Scholar
PubMed
Close
 MD
, and
Amit Mahipal Mayo Clinic Minnesota, Rochester, MN

Search for other papers by Amit Mahipal in
Current site
Google Scholar
PubMed
Close
 MD, MPH

Purpose: Patients with advanced BTCs have therapeutic options. After progression on gemcitabine and cisplatin, there is no standard of care option available. In our previous phase II trial, we had demonstrated activity with single agent trifluridine/tipiracil, in advanced, refractory BTCs. Here, we determine the safety and efficacy of trifluridine/tipiracil in combination with irinotecan in a phase II trial setting for refractory, advanced unresectable BTCs. Methods: In this single-arm, open-label phase II clinical trial, 28 patients (27 evaluable patients) were enrolled and were treated with: trifluridine/tipiracil is 25 mg/m2 (days 1-5 of 14 day-cycle) and irinotecan 180 mg/m2 (day 1 of the 14-day cycle). The primary endpoint for the study was 16-week PFS rate. 2-stage Simon design was used for early stopping for futility, where 6 or more successes in first 25 evaluable patients would be a successful trial. This study had 80% power to detect a true 16-week PFS rate of 30%, with a 5% significance level when the true 16-week PFS rate is 10%. Patients with BTCs who had progressed on at least one line of systemic therapy were eligible. Pre-treatment biopsies were performed for organoid development. Results: The median age was 68 years and subtypes were intrahepatic (59%), extrahepatic (33%) and gallbladder cancer (8%). No. of prior lines of therapies included: 1 (37%), 2 (41%), ≥3 (22%). 16-week PFS was 37% (10/27; 95% CI: (19-58%)), thereby meeting the criteria for success for the primary endpoint. The ORR and DCR were 20% and 45%, respectively. Median OS was 52.6 weeks (95% CI: 33.6-NE). The most common grade 3/4 toxicities were neutropenia (29%), lymphopenia (15%), hypertension (15%), thrombocytopenia (11%), elevated alkaline phosphatase (11%), fatigue (7%), and diarrhea (7%). 9 out of 27 (33%) and 14/27 (52%) had dose reductions secondary to AEs (cytopenias and fatigue) for trifluridine/tipiracil and irinotecan, respectively and 1 patient discontinued the therapy due to adverse events. Conclusions: The combination of trifluridine/tipiracil plus irinotecan is a safe and efficacious treatment for refractory metastatic and unresectable BTCs. PFS and OS outcomes are promising compared to previous trials in advanced BTCs. A larger randomized trial is needed to confirm these results. This study was approved and funded in part by the NCCN Oncology Research Program from general research support provided by Taiho Oncology, Inc.

Corresponding Author: Amit Mahipal, MD MPH
  • Collapse
  • Expand